Inclusion Criteria:  Patients who received at least 3 cycles of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 or higher peripheral neuropathy as a result of motor and sensory neuropathy evaluation (lung cancer, breast cancer, gynecological cancers, colorectal cancers), Patients with stable vital signs who can tolerate exercise, No bone metastases, Patients older than 18 years old, Patients who agree to participate in the study will participate.  Exclusion Criteria:  Newly starting chemotherapy, Peripheral neuropathy due to problems other than chemotherapy (tumor compression, nutritional disorders, infections and systemic diseases such as diabetes mellitus), Vital signs that cannot tolerate exercise are non-stable, Bone metastases, Patients with impaired skin integrity in their hands and feet and who do not agree to participate in the study will not be included in the study.